Navigation Links
China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
Date:3/26/2008

HANGZHOU, China, March 26 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced today that it has reached agreement with Beijing Keyuan Xinhai Pharmaceutical Company to launch newly approved pharmaceutical products made by leading international pharmaceutical companies. According to the agreement, China Biopharma will distribute pharmaceutical products made by international companies including human vaccines in China using its sales network and distribution logistics.

In the last few months, the company has made effort to extend its market scope and establish new partnership in addition to the original JV partner, Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd. Due to certain local tax regulations the Company's sales of the products of its original JV partner could not be fully recognized. In order to effectively conduct its business operation and change from its passive marketing approach in China, the Company has shifted its market strategy to working more closely with new pharmaceutical products from global leading pharmaceutical companies in addition to local products. "We are very excited about the agreement we have reached with Beijing Keyuan Xinhai Pharmaceutical Company," said Mr. Qiumeng Wang, the Company's COO. "It will significantly improve our current operation situation." Beijing Keyuan Xinhai Pharmaceutical Company is one of the largest imported pharmaceutical product providers in China.

About China Biopharma, Inc.

China Biopharma Inc. is a biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its local presents and the relationship with local Chinese bio-pharmaceutical companies and international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.

Safe Harbor Statement

Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

CONTACT:

China Biopharma, Inc.

Tel: +1 (609) 651-8588

ir@chinabiopharma.net

http://www.chinabiopharma.net


'/>"/>
SOURCE China Biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... VetStem Biopharma, Inc ., ... laboratory in Poway, California. Based upon 12 years of knowledge gained by ... consultants, VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing plant. ...
(Date:2/21/2017)... , Feb. 21, 2017  Lexus, a returning partner of ... as the official and exclusive automobile partner of the men,s and ... race. The 2017 Amgen Tour of California ... and feature some of the best professional cycling teams in the ... May 14-20. The four-day Amgen Breakaway from Heart Disease TM ...
(Date:2/21/2017)... FRANCISCO , Feb. 21, 2017   Invitae ... genetic information companies, today announced that members of the ... Company 37th Annual Health Care Conference on Monday, March ... p.m. Pacific in Boston, Massachusetts . ... presentation may be accessed by visiting the investors section ...
(Date:2/20/2017)... , Feb. 20, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... President and CEO and Fabrice Orecchioni, the company,s COO, has been ... COO over the past four years, Fabrice has overseen the construction, ... and the management of the Mitsui JV.  Fabrice has ... the proposed China JV. ...
Breaking Biology Technology:
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
Breaking Biology News(10 mins):